|
|
|
Feed Submission If you'd like OHCNetwork Health News to link to your health news or blog from this category (Irritable-Bowel Syndrome - Digestion - Diseases and Conditions), please submit your RSS or XML feed to OHCNetwork Health News. Contact information is available here. |
Health News >> Diseases and Conditions >> Digestion >> Irritable-Bowel Syndrome
Irritable-Bowel Syndrome News
Irritable-Bowel Syndrome News From Medical News Today
Irritable bowel syndrome is a chronic, debilitating disorder affecting 25 million people in the U.S -- 14-24 percent of women and 5-19 percent of men. No reliable and satisfactory medical treatment exists for the full range of IBS symptoms, which can cause severe physical and psychological distress and deprive sufferers of their quality of life.
Irritable-Bowel Syndrome News From Medical News Today
According to a study published on bmj.com, doctors should recommend fiber, antispasmodics, and peppermint oil as first-line treatments for irritable bowel syndrome (IBS). Recent proof of the effectiveness of these treatments should also lead to changes in the national guidelines that specify how to manage IBS. Affecting between 5% and 20% of the population, IBS is a condition that causes abdominal pain and irregular bowel movements.
Irritable-Bowel Syndrome News From Medical News Today
Researchers in Spain and the United Kingdom are reporting development of a faster test for identifying the food protein that triggers celiac disease, a difficult-to-diagnose digestive disease involving the inability to digest protein called gluten that occurs in wheat, oats, rye, and barley. The finding could help millions of people avoid diarrhea, bloating, and other symptoms that occur when they unknowingly eat foods containing gluten.
Irritable-Bowel Syndrome News From Medical News Today
At this week's opening of the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition (Atlanta, USA, November 16-20, 2008) Philips Research will announce its new intelligent pill technology "iPill", targeted at assisting drug development and enabling new therapies for debilitating and life-threatening digestive tract disorders such as Crohn's disease, colitis and colon cancer.
Irritable-Bowel Syndrome News From Medical News Today
The tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St. Louis. The researchers indicate that the immune cells could have a therapeutic role in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.
Irritable-Bowel Syndrome News From Medical News Today
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis.
Irritable-Bowel Syndrome News From Medical News Today
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO? (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis.
Irritable-Bowel Syndrome News From Medical News Today
Alvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed that single doses of up to 1,800 mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300 mg level achieved up to a 96% reduction of gluten in a meal in the stomach at 30 minutes, and were well tolerated by patients with celiac disease.
Irritable-Bowel Syndrome News From Medical News Today
To help those with inflammatory bowel disease (IBD) be better informed and involved in managing their disease, the European Foundation of Crohn's & Ulcerative Colitis Associations (EFCCA) has launched a new series of guides titled "Life and IBD". For over one million people across Europe who have it, IBD can be an overwhelming experience with new physicians, medications and terminology.
Irritable-Bowel Syndrome News From Medical News Today
Shire Limited, the global specialty biopharmaceutical company, announces that data published in Gut show that 64.4% of patients with mild to moderate ulcerative colitis (UC) who achieved clinical and endoscopic remission maintained this at 12 months when given two mesalazine 1200mg gastro-resistant, prolonged release tablets (Mezavant XL) once a day as a maintenance therapy.
Irritable-Bowel Syndrome News From Medical News Today
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis (UC) patients who switched from another 5-ASA product (78 percent of relapse-free subjects vs. 59 percent [P
Irritable-Bowel Syndrome News From Medical News Today
Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) announced the presentation of results from a Phase 2b study assessing linaclotide's safety and efficacy in 420 patients with irritable bowel syndrome with constipation (IBS-C).
Irritable-Bowel Syndrome News From Medical News Today
The Johns Hopkins University School of Medicine and the American Academy of Nurse Practitioners (AANP) today announced the launch of the Performance Improvement component of the Educational Initiative on Constipation (EIC) at the Collective Clinical Forum: EIC, a satellite symposium that took place during the American College of Gastroenterology (ACG) annual meeting on October 5, 2008, in Orlando, Fla.
Irritable-Bowel Syndrome News From Medical News Today
Several studies presented at the American College of Gastroenterology's 73rd Annual Scientific Meeting in Orlando highlight the safety and efficacy of probiotics in improving symptoms and normalizing bowel movement frequency in patients suffering from constipation or diarrhea related to Irritable Bowel Syndrome (IBS).
Irritable-Bowel Syndrome News From Medical News Today
Vitamin D replacement may be necessary to reverse deficiency-related bone loss New research presented at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found patients with inflammatory bowel disease or chronic liver disease were at increased risk of developing Vitamin D deficiencies. Two separate studies highlight the importance of regular Vitamin D checkups in the evaluation of patients with certain digestive diseases.
Irritable-Bowel Syndrome News From Medical News Today
Ironwood Pharmaceuticals (formerly Microbia) announced presentation of data from a pair of preclinical studies delineating the role that cyclic guanosine monophosphate (cGMP) plays in alleviating intestinal pain. These studies demonstrate that cGMP inhibits intestinal pain in a preclinical model of intestinal hyperalgesia and desensitizes colonic afferent nerves in a similar model of experimental colitis.
Irritable-Bowel Syndrome News From Medical News Today
New research on the benefits of probiotics in children and seniors was presented at The American College of Nutrition (ACN) Annual Meeting in a symposium, "Practical Applications of Probiotics in Health and Disease." Scientific experts in the fields of pediatrics, aging, and nutrition discussed the potential uses for probiotics in children as well as the elderly, and for health conditions such as Inflammatory Bowel Disease (IBD).
Irritable-Bowel Syndrome News From Medical News Today
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced findings from two analyses of a Phase II clinical trial that demonstrate the utility of rifaximin, a non-absorbed, gut-selective antibiotic, in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS).
Irritable-Bowel Syndrome News From Medical News Today
Scientists report online in Nature that they have linked the health of specialized gut immune cells to a gene associated with Crohn's disease, an often debilitating and increasingly prevalent inflammatory bowel disorder. The link to immune cells intrigued researchers at Washington University School of Medicine in St. Louis because they and others believe Crohn's disease is caused by misdirected immune responses in the intestine that damage gut tissue.
Irritable-Bowel Syndrome News From Medical News Today
Ore Pharmaceuticals Inc. (NASDAQ: ORXE) announced today that it has initiated dosing subjects with GL1001, the Company's lead drug candidate, in a multiple ascending dose clinical trial. GL1001, the first clinical-stage inhibitor of the ACE2 enzyme, is an orally administered small molecule that has decreased several disease activity measures in in vivo models of inflammatory bowel disease (IBD) and gastritis.
Irritable-Bowel Syndrome News From Medical News Today
Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc. (NYSE: FRX) announced they will present results of a Phase 2b study investigating linaclotide's safety and efficacy in 419 patients with irritable bowel syndrome with constipation (IBS-C) in a plenary session at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting in Orlando, Fla. on October 7, 2008.
Irritable-Bowel Syndrome News From Medical News Today
The Johns Hopkins University School of Medicine, Office of Continuing Medical Education (JHU) and the American Academy of Nurse Practitioners (AANP) announced today the launch of the Educational Initiative on Constipation (EIC) Award for Clinical Excellence (ACETM) program.
Irritable-Bowel Syndrome News From Medical News Today
Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment. It is important to alert health professionals about prevention and early diagnosis of HBV infection because the steroids and immunosuppressant drugs used in IBD treatment worsen the HBV liver disease.
Irritable-Bowel Syndrome News From Medical News Today
The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has funded a £1.6 million clinical trial to compare two powerful drugs for people with steroid resistant acute severe ulcerative colitis (UC). UC affects approximately 150,000 people in the UK and is a major burden on patients and NHS resources, as it often leads to severe morbidity, grossly impaired quality of life, frequent and long inpatients stays and emergency colectomy.
Irritable-Bowel Syndrome News From Medical News Today
SIBO is a common feature in IBS and in fact may be directly related to the genesis of IBS symptoms. An ERBHAL on a lactulose breath test may indicate SIBO. Antibiotics and elemental diets have been shown to be effective in treating SIBO, but the efficacy of probiotics is untested. A pilot study was undertaken to determine the effect of L. strain Shirota (Yakult(R)) on intestinal fermentation patterns of IBS patients.
| ||||||||||||||||||
| ||||||||||||||||||